Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial

INTRODUCTION: Luseogliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, promotes urinary glucose excretion (UGE) and reduces plasma glucose concentrations. Luseogliflozin was approved for use in Japan after favorable pharmacokinetic, pharmacodynamic, and safety profiles were repo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Autores principales: Sasaki, Takashi, Seino, Yutaka, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4415995/
https://ncbi.nlm.nih.gov/pubmed/25855342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0200-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares